Cargando…
BNT162b2 mRNA COVID-19 Vaccine Does Not Impact the Honeymoon Phase in Type 1 Diabetes: A Case Report
Type 1 diabetes (T1D), which is caused by the autoimmune destruction of insulin-secreting pancreatic beta cells, represents a high-risk category requiring COVID-19 vaccine prioritization. Although COVID-19 vaccination can lead to transient hyperglycemia (vaccination-induced hyperglycemia; ViHG), its...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9319173/ https://www.ncbi.nlm.nih.gov/pubmed/35891261 http://dx.doi.org/10.3390/vaccines10071096 |
_version_ | 1784755484899672064 |
---|---|
author | Infante, Marco Fabbri, Andrea Padilla, Nathalia Pacifici, Francesca Di Perna, Pasquale Vitiello, Laura Feraco, Alessandra Giuliano, Maria Passeri, Marina Caprio, Massimiliano Ricordi, Camillo Della-Morte, David Uccioli, Luigi |
author_facet | Infante, Marco Fabbri, Andrea Padilla, Nathalia Pacifici, Francesca Di Perna, Pasquale Vitiello, Laura Feraco, Alessandra Giuliano, Maria Passeri, Marina Caprio, Massimiliano Ricordi, Camillo Della-Morte, David Uccioli, Luigi |
author_sort | Infante, Marco |
collection | PubMed |
description | Type 1 diabetes (T1D), which is caused by the autoimmune destruction of insulin-secreting pancreatic beta cells, represents a high-risk category requiring COVID-19 vaccine prioritization. Although COVID-19 vaccination can lead to transient hyperglycemia (vaccination-induced hyperglycemia; ViHG), its influence on the course of the clinical remission phase of T1D (a.k.a. “honeymoon phase”) is currently unknown. Recently, there has been an increasing concern that COVID-19 vaccination may trigger autoimmune phenomena. We describe the case of a 24-year-old young Italian man with T1D who received two doses of the BNT162b2 mRNA (Pfizer-BioNTech) COVID-19 vaccine during a prolonged honeymoon phase. He experienced a transient impairment in glucose control (as evidenced by continuous glucose monitoring) that was not associated with substantial changes in stimulated C-peptide levels and islet autoantibody titers. Nonetheless, large prospective studies are needed to confirm the safety and the immunometabolic impact of the BNT162b2 vaccine in T1D patients during the honeymoon phase. Thus far, T1D patients who are going to receive COVID-19 vaccination should be warned about the possible occurrence of transient ViHG and should undergo strict postvaccination surveillance. |
format | Online Article Text |
id | pubmed-9319173 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-93191732022-07-27 BNT162b2 mRNA COVID-19 Vaccine Does Not Impact the Honeymoon Phase in Type 1 Diabetes: A Case Report Infante, Marco Fabbri, Andrea Padilla, Nathalia Pacifici, Francesca Di Perna, Pasquale Vitiello, Laura Feraco, Alessandra Giuliano, Maria Passeri, Marina Caprio, Massimiliano Ricordi, Camillo Della-Morte, David Uccioli, Luigi Vaccines (Basel) Case Report Type 1 diabetes (T1D), which is caused by the autoimmune destruction of insulin-secreting pancreatic beta cells, represents a high-risk category requiring COVID-19 vaccine prioritization. Although COVID-19 vaccination can lead to transient hyperglycemia (vaccination-induced hyperglycemia; ViHG), its influence on the course of the clinical remission phase of T1D (a.k.a. “honeymoon phase”) is currently unknown. Recently, there has been an increasing concern that COVID-19 vaccination may trigger autoimmune phenomena. We describe the case of a 24-year-old young Italian man with T1D who received two doses of the BNT162b2 mRNA (Pfizer-BioNTech) COVID-19 vaccine during a prolonged honeymoon phase. He experienced a transient impairment in glucose control (as evidenced by continuous glucose monitoring) that was not associated with substantial changes in stimulated C-peptide levels and islet autoantibody titers. Nonetheless, large prospective studies are needed to confirm the safety and the immunometabolic impact of the BNT162b2 vaccine in T1D patients during the honeymoon phase. Thus far, T1D patients who are going to receive COVID-19 vaccination should be warned about the possible occurrence of transient ViHG and should undergo strict postvaccination surveillance. MDPI 2022-07-08 /pmc/articles/PMC9319173/ /pubmed/35891261 http://dx.doi.org/10.3390/vaccines10071096 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Case Report Infante, Marco Fabbri, Andrea Padilla, Nathalia Pacifici, Francesca Di Perna, Pasquale Vitiello, Laura Feraco, Alessandra Giuliano, Maria Passeri, Marina Caprio, Massimiliano Ricordi, Camillo Della-Morte, David Uccioli, Luigi BNT162b2 mRNA COVID-19 Vaccine Does Not Impact the Honeymoon Phase in Type 1 Diabetes: A Case Report |
title | BNT162b2 mRNA COVID-19 Vaccine Does Not Impact the Honeymoon Phase in Type 1 Diabetes: A Case Report |
title_full | BNT162b2 mRNA COVID-19 Vaccine Does Not Impact the Honeymoon Phase in Type 1 Diabetes: A Case Report |
title_fullStr | BNT162b2 mRNA COVID-19 Vaccine Does Not Impact the Honeymoon Phase in Type 1 Diabetes: A Case Report |
title_full_unstemmed | BNT162b2 mRNA COVID-19 Vaccine Does Not Impact the Honeymoon Phase in Type 1 Diabetes: A Case Report |
title_short | BNT162b2 mRNA COVID-19 Vaccine Does Not Impact the Honeymoon Phase in Type 1 Diabetes: A Case Report |
title_sort | bnt162b2 mrna covid-19 vaccine does not impact the honeymoon phase in type 1 diabetes: a case report |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9319173/ https://www.ncbi.nlm.nih.gov/pubmed/35891261 http://dx.doi.org/10.3390/vaccines10071096 |
work_keys_str_mv | AT infantemarco bnt162b2mrnacovid19vaccinedoesnotimpactthehoneymoonphaseintype1diabetesacasereport AT fabbriandrea bnt162b2mrnacovid19vaccinedoesnotimpactthehoneymoonphaseintype1diabetesacasereport AT padillanathalia bnt162b2mrnacovid19vaccinedoesnotimpactthehoneymoonphaseintype1diabetesacasereport AT pacificifrancesca bnt162b2mrnacovid19vaccinedoesnotimpactthehoneymoonphaseintype1diabetesacasereport AT dipernapasquale bnt162b2mrnacovid19vaccinedoesnotimpactthehoneymoonphaseintype1diabetesacasereport AT vitiellolaura bnt162b2mrnacovid19vaccinedoesnotimpactthehoneymoonphaseintype1diabetesacasereport AT feracoalessandra bnt162b2mrnacovid19vaccinedoesnotimpactthehoneymoonphaseintype1diabetesacasereport AT giulianomaria bnt162b2mrnacovid19vaccinedoesnotimpactthehoneymoonphaseintype1diabetesacasereport AT passerimarina bnt162b2mrnacovid19vaccinedoesnotimpactthehoneymoonphaseintype1diabetesacasereport AT capriomassimiliano bnt162b2mrnacovid19vaccinedoesnotimpactthehoneymoonphaseintype1diabetesacasereport AT ricordicamillo bnt162b2mrnacovid19vaccinedoesnotimpactthehoneymoonphaseintype1diabetesacasereport AT dellamortedavid bnt162b2mrnacovid19vaccinedoesnotimpactthehoneymoonphaseintype1diabetesacasereport AT uccioliluigi bnt162b2mrnacovid19vaccinedoesnotimpactthehoneymoonphaseintype1diabetesacasereport |